Table 2.
Profile of drug resistance mutations in treatment naïve and subjects on ART.
| Sample ID | Treatment status | Resistance mutations | Subtypes | ||
|---|---|---|---|---|---|
| NRTI | NNRTI | PI | |||
| NACMR091 | Naive | M184V | Y181C | — | 02_AG |
| NA2CMR220 | Naive | T69D | K103N, P225H | V11I, K20I | 02_AG |
| NACMR095 | Naive | — | V108I | K20I | 02_AG |
| NA2CMR305 | Naive | — | K101E | K20I | 18_cpx |
| NA2CMR331 | Naive | — | Y188L | — | URF |
| NA2CMR116 | Naive | M184V, T215F | K103N, E138Q | K20I | 02_AG |
| NA2CMR171 | Naive | K65R, Y115F, M184V | L100I, K103N | K20I | 02_AG |
| NA2CMR189 | Naive | — | K103N | K20I | 02_AG |
| NA2CMR157 | 3TC-AZT-NVP | D67N, K70R, M184V, K219Q | K103N | V82L | D |
| NA2CMR137 | 3TC-AZT-NVP | M184V, T215F | V106A, P225H | K20I | 02_AG |
| NA2CMR176 | 3TC-AZT-NVP | M184V | Y188L | K20I | 02_AG |
| NACMR039 | 3TC-TDF-LPV/r | K219E | Y181C | K20I | 02_AG |
| NA2CMR029 | 3TC-AZT-NVP | M184V | — | L10I | A1 |
| NA2CMR051 | 3TC-AZT-NVP | D67N, K70R, M184V, K219Q | K103N, H221Y | L10I | 11_cpx |
| NA2CMR110 | 3TC-AZT-EFV | M184V | K103N | — | 11_cpx |
| NA2CMR151 | 3TC-AZT-NVP | T69N, K70R, M184V, K219Q | Y181C | L10I, K20I | 02_AG |
| NA2CMR251 | 3TC-TDF-EFV | M184V | L100I, V106A | K20I | URF |
| NA2CMR249 | 3TC-AZT-EFV | — | V108I, | K20I | 02_AG |
| NA2CMR334 | 3TC-AZT-NVP | M184V, T215F | V106M | K20V | G |
AZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; TDF: Tenovofir; LPV/r: Lopinavir/ritonavir; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNRTI: Non-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor; PI: Protease Inhibitor (minor resistance mutations are in italic).